缺陷不匹配修复系统/微卫星不稳定性-高结直肠癌患者的第二次恶性瘤
Paul Franques1,2, Pierre Moreau3, Camille Evrard1,2
1Medical Oncology Department, Poitiers University Hospital, Poitiers, France.
Therapeutic advances in gastroenterology
|June 23, 2025
概括
患有缺陷不匹配修复/微卫星不稳定性高 (dMMR/MSI-H) 大肠直肠癌 (CRC) 的患者患第二种原发性癌症 (APC) 的风险很高. 这种风险与林奇综合征和零星病例相似,突出了需要谨慎跟进的需要.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 癌症研究 癌症研究
背景情况:
- 缺陷不匹配修复 (dMMR) 或微卫星不稳定性高 (MSI-H) 现型的结肠直肠癌 (CRC) 约占所有CRC的12%.
- 这种表型是由生殖基因突变 (林奇综合征,LS) 或MLH1的表观遗传沉默 (零星病例) 引起的.
- 虽然LS患者已知患有各种dMMR/MSI-H癌症的风险增加,但在零星的dMMR/MSI-HCRC中,第二种原发性癌症 (APC) 的风险知之甚少.
研究的目的:
- 在被诊断为dMMR/MSI-H CRC的患者中确定患另一种原发性癌症 (APC) 的风险.
- 为了比较林奇综合征 (LS) 和零星的dMMR/MSI-H CRC病例之间的APC发生率.
- 描述这些次要瘤的不匹配修复 (MMR) 现型.
主要方法:
- 分析了484名患有dMMR/MSI-HCRC的患者的前性队列.
- 评估了APC的发生 (在指数CRC之前或之后).
- 患者数据根据LS与零星状态进行了分层,并比较了具有和没有APC的患者的特征.
主要成果:
- 在484名患者中,有116名 (24.0%) 患有APC病史,平均每名患者增加1.4个瘤.
- 最常见的APC部位是皮肤 (24.7%) 和乳房 (18.5%).
- 在LS (25.0%) 和零星 (24.8%) dMMR/MSI-H CRC组中,APC的风险相似. 在任何一个子组中都没有确定APC的特定风险因素. 在零星病例中,只有3.8%的APC是dMMR/MSI-H,而LS病例中为50.0%.
结论:
- 患有dMMR/MSI-HCRC病史的患者,包括零星病例,面临患第二原发性瘤的显著风险.
- 由于这种风险增加,定期监测dMMR/MSI-HCRC患者至关重要.
- 在零星的dMMR/MSI-HCRC患者的第二种癌症中,很少表现出dMMR/MSI-H表型.
更多相关视频
相关概念视频
Mismatch Repair
5.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.2K
Cancers Originate from Somatic Mutations in a Single Cell
13.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.1K


